Abstract
Patients with ovarian cancer have a high risk of developing thrombosis. We aimed to investigate pre and post operative biomarkers associated with thrombosis including deep vein thrombosis and pulmonary thromboembolism in patients treated for ovarian cancer. We collected pre and post operative blood samples from 133 patients undergoing surgery for ovarian cancer between December 2021 and August 2022. The measured parameters were white blood cell count, hemoglobin, platelets, monocytes, serum glucose, CA125, D-dimer, fibrinogen, prothrombin time, activated partial thromboplastin time, fibrinogen degradation products, antithrombin III, protein C, protein S, plasminogen, plasminogen activator inhibitor 1, homocysteine, N-terminal pro-brain natriuretic peptide, interleukin 6, thrombopoietin, soluble P-selectin and granulocyte stimulating factor. Body mass index of patients were collected. Differences between patients who developed thrombosis and those without were compared with Wilcoxon rank-sum test and we analyzed the continuous variables using logistic regression. Twenty-one (15.8%) patients developed thrombosis ranging from 6 to 146 days (median 15 days) after surgery. Pre operative values of homocysteine (p = 0.033) and IL-6 (p = 0.043) were significantly increased and post operative aPTT (p = 0.022) was prolonged and plasminogen (p = 0.041) was decreased in patients with thrombosis. It is important to find novel biomarkers for thrombosis to carefully manage patients who are prone to develop thrombosis despite preventive measures were applied.
This is a preview of subscription content, log in via an institution to check access.
Data availability
Data will be provided based on its usage.
References
Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW (2008) Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 111:4902–4907
Metcalf RL, Fry DJ, Swindell R, McGurk A, Clamp AR, Jayson GC et al (2014) Thrombosis in ovarian cancer: a case control study. Br J Cancer 110:1118–1124
Satoh T, Oki A, Uno K, Sakurai M, Ochi H, Okada S et al (2007) High incidence of silent venous thromboembolism before treatment in ovarian cancer. Br J Cancer 97:1053–1057
Uno K, Homma S, Satoh T, Nakanishi K, Abe D, Matsumoto K et al (2007) Tissue factor expression as a possible determinant of thromboembolism in ovarian cancer. Br J Cancer 96:290–295
Ay C, Simanek R, Vormittag R, Dunkler D, Alguel G, Koder S et al (2008) High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and thrombosis study (CATS). Blood 112:2703–2708
Undas A, Brozek J, Szczeklik A (2005) Homocysteine and thrombosis: from basic science to clinical evidence. Thromb Haemost 94:907–915
Signorelli SS, Valerio F, Davide C, Oliveri Conti G, Maria F, Ignazio M et al (2017) Evaluating the potential of routine blood tests to identify the risk of deep vein thrombosis: a 1-Year Monocenter Cohort Study. Angiology 68:592–597
Hisada Y, Mackman N (2017) Cancer-associated pathways and biomarkers of venous thrombosis. Blood 130:1499–1506
Homocysteine Studies C (2002) Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 288:2015–2022
Dayal S, Wilson KM, Leo L, Arning E, Bottiglieri T, Lentz SR (2006) Enhanced susceptibility to arterial thrombosis in a murine model of hyperhomocysteinemia. Blood 108:2237–2243
Kasuga I, Makino S, Kiyokawa H, Katoh H, Ebihara Y, Ohyashiki K (2001) Tumor-related leukocytosis is linked with poor prognosis in patients with lung carcinoma. Cancer 92:2399–2405
Ghasemzadeh M, Ahmadi J, Hosseini E (2022) Platelet-leukocyte crosstalk in COVID-19: how might the reciprocal links between thrombotic events and inflammatory state affect treatment strategies and disease prognosis? Thromb Res 213:179–194
Deitcher SR, Carman TL, Kottke-Marchant K (2002) Simultaneous deep venous thrombosis and acquired factor VIII inhibitor. Clin Appl Thromb Hemost 8:375–379
Miyata T, Iwanaga S, Sakata Y, Aoki N (1982) Plasminogen Tochigi: inactive plasmin resulting from replacement of alanine-600 by threonine in the active site. Proc Natl Acad Sci U S A 79:6132–6136
Lisman T, de Groot PG, Meijers JC, Rosendaal FR (2005) Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis. Blood 105:1102–1105
Bollen L, Peetermans M, Peeters M, Van Steen K, Hoylaerts MF, Declerck PJ et al (2014) Active PAI-1 as marker for venous thromboembolism: case-control study using a comprehensive panel of PAI-1 and TAFI assays. Thromb Res 134:1097–1102
Funding
This study was funded by the National Cancer Center, Korea (Grant No.2111020), and the National Research Foundation of Korea (Grant No.2020R1A2C2010566).
Author information
Authors and Affiliations
Contributions
Concept and design: HE Shim, Analysis and interpretation of data: DE Lee, Critical writing or revising the intellectual content: YJ Lee, JH Kim, MC Lim, SY Park, MH Kwak, Final approval of the version to be published: SY Kong.
Corresponding authors
Ethics declarations
Ethical approval
This study was approved by the Institutional Review Board of the National Cancer Center in Korea (IRB No. NCC2021-0059).
Competing interests
All authors declare no competing interests.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Shim, H., Kim, J.H., Lee, DE. et al. Prospective analysis of pre and postoperative laboratory parameters associated with thrombosis in patients with ovarian cancer. J Thromb Thrombolysis 57, 492–496 (2024). https://doi.org/10.1007/s11239-023-02944-1
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11239-023-02944-1